Business Context and Reporting Period
Company: Oragenics, Inc. (ONI BioPharma Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2008
Listing Status: American Stock Exchange (AMEX) under symbol "ONI"
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses the following financial conditions triggering regulatory action:
- Shareholders' Equity: Less than the required $4,000,000.
- Profitability: The Company has reported losses from continuing operations and net losses in three of its four most recent fiscal years.
Material Changes and Compliance Issues
On May 14, 2008, the Company received a notice from the AMEX indicating non-compliance with Section 1003(a)(ii) of the AMEX Company Guide based on reviews of the Form 10-KSB (year ended December 31, 2007) and Form 10-Q (period ended March 31, 2008). This is a new compliance issue distinct from a previously addressed non-compliance with Section 1003(a)(i), for which a plan was already approved.
Outlook, Management Commentary, and Risks
Compliance Plan: The Company intends to submit a "Revised Plan" to address the equity and loss requirements by June 13, 2008.
Timeline: AMEX has granted an extension until October 27, 2008, to regain full compliance.
Risks:
- There is no assurance that AMEX will accept the Revised Plan.
- If the plan is rejected or compliance is not achieved by October 27, 2008, the Company may be subject to delisting proceedings.
- Continued listing, even if the plan is accepted, will be subject to periodic review.
Investor Verification Checklist
- Verify the submission and acceptance status of the Revised Plan by June 13, 2008.
- Monitor the Company's shareholders' equity to ensure it approaches or exceeds the $4,000,000 threshold.
- Review upcoming financial reports for evidence of reduced losses or a path to profitability.
- Watch for any further notices from AMEX regarding delisting proceedings prior to the October 27, 2008 deadline.